North Carolina-based Belhaven Biopharma announced that it has closed a funding round that raised $11 million for continued development of the company’s Nasdepi intranasal dry powder epinephrine for the treatment of anaphylaxis. The company said that the funds will support the completion of clinical development and preparations for an NDA submission. Belhaven also announced the initiation of a dose finding study that will include a nasal allergen challenge.
Belhaven CEO Scott Lyman commented, “This next clinical study is a crucial step in confirming the safety, efficacy, and bioavailability of Nasdepi as demonstrated in our earlier trial and in comparison to traditional autoinjectors. By testing the product under real-world conditions, including a nasal allergen challenge, we aim to confirm its potential as a reliable, easy to use solution for anaphylaxis, bringing us closer to addressing critical gaps in allergy care.”
Read the Belhaven Biopharma press release
